Sight Sciences, Inc. (NASDAQ:SGHT) CTO Sells $12,482.54 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 3,829 shares of the firm’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $3.26, for a total value of $12,482.54. Following the completion of the sale, the chief technology officer now directly owns 1,749,541 shares of the company’s stock, valued at $5,703,503.66. The trade was a 0.22 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

David Badawi also recently made the following trade(s):

• On Friday, January 3rd, David Badawi sold 3,111 shares of Sight Sciences stock. The stock was sold at an average price of $3.52, for a total transaction of $10,950.72.

Sight Sciences Stock Performance

Shares of SGHT opened at $3.25 on Friday. The company has a quick ratio of 9.74, a current ratio of 10.18 and a debt-to-equity ratio of 0.36. The stock has a market cap of $164.95 million, a P/E ratio of -3.19 and a beta of 2.57. The business’s 50 day moving average price is $3.82 and its 200-day moving average price is $5.52. Sight Sciences, Inc. has a 52 week low of $3.16 and a 52 week high of $8.45.

Sight Sciences (NASDAQ:SGHT) last released its earnings results on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. The business had revenue of $20.16 million for the quarter, compared to the consensus estimate of $20.41 million. Equities research analysts anticipate that Sight Sciences, Inc. will post -1.01 earnings per share for the current fiscal year.

Institutional Trading of Sight Sciences

A number of institutional investors and hedge funds have recently bought and sold shares of the company. SG Americas Securities LLC bought a new position in shares of Sight Sciences in the third quarter worth approximately $75,000. The Manufacturers Life Insurance Company purchased a new position in Sight Sciences in the 2nd quarter worth approximately $95,000. GSA Capital Partners LLP bought a new position in Sight Sciences in the 3rd quarter valued at approximately $136,000. American Century Companies Inc. boosted its stake in Sight Sciences by 31.1% during the 2nd quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock valued at $240,000 after purchasing an additional 8,527 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in shares of Sight Sciences by 40.1% in the 2nd quarter. Rhumbline Advisers now owns 40,811 shares of the company’s stock worth $272,000 after purchasing an additional 11,671 shares in the last quarter. 55.51% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on SGHT shares. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research report on Friday, November 8th. Piper Sandler reiterated a “neutral” rating and set a $5.50 target price (down previously from $6.00) on shares of Sight Sciences in a report on Friday, November 8th. Lake Street Capital lowered Sight Sciences from a “buy” rating to a “hold” rating and decreased their target price for the stock from $10.00 to $5.00 in a research report on Monday, November 4th. UBS Group assumed coverage on Sight Sciences in a research report on Friday, December 6th. They set a “buy” rating and a $5.50 price target on the stock. Finally, Morgan Stanley decreased their price objective on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a report on Monday, November 11th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $5.12.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.